{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:42:51Z","timestamp":1789558971432,"version":"build-2803163510"},"reference-count":28,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,3,15]]},"abstract":"<jats:p>Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course. On the basis of possible biologic differences, the new World Health Organization (WHO) classification of lymphoma suggests further subdivision of FL3 into grades 3a and 3b and states that the percentage of involvement by diffuse large B-cell lymphoma (DLBCL) should also be reported. However, the clinical implications of these features are unclear. Therefore, we studied 190 newly diagnosed patients with lymph node\u2013based FL3 who received anthracycline-containing combination chemotherapy. The follicular component was subclassified as grade 3a (FL3a) or grade 3b (FL3b) according to the WHO criteria, or as follicular large cleaved cell type (FLC). The percentage of a diffuse component, if present, was also recorded. Of the 190 cases, there were 107 FL3a (56%), 53 FL3b (28%), and 30 FLC (16%) cases. Diffuse areas were seen in 72 cases (31 FL3a, 28 FL3b, and 13 FLC). There were no significant differences in the clinical characteristics, overall survival, or event-free survival between patients with grades FL3a, FL3b, or FLC. However, those cases with a predominant diffuse component (&gt;\u200950% diffuse) had a significantly worse overall survival (P\u2009=\u2009.0037) and event-free survival (P\u2009=\u2009.012). Therefore, we conclude that the subdivision of FL3 into cytologic subtypes does not appear to be important clinically. However, patients with FL3 having a diffuse component of more than 50% have an inferior survival that is similar to the survival of those with DLBCL.<\/jats:p>","DOI":"10.1182\/blood-2002-07-2298","type":"journal-article","created":{"date-parts":[[2003,2,27]],"date-time":"2003-02-27T18:28:53Z","timestamp":1046370533000},"page":"2363-2367","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":114,"title":["A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival"],"prefix":"10.1182","volume":"101","author":[{"given":"Christine P.","family":"Hans","sequence":"first","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Weisenburger","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Hock","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Aoun","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Greiner","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Bociek","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822121598300_B1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood."},{"key":"2019111822121598300_B2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood.V56.1.98.bloodjournal56198","article-title":"Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival.","volume":"56","author":"Osborne","year":"1980","journal-title":"Blood."},{"key":"2019111822121598300_B3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19820301)49:5<840::AID-CNCR2820490503>3.0.CO;2-9","article-title":"Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy.","volume":"49","author":"Glick","year":"1982","journal-title":"Cancer."},{"key":"2019111822121598300_B4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/JCO.1984.2.7.811","article-title":"Follicular large cell lymphoma: analysis and prognostic factors in 62 patients.","volume":"2","author":"Kantarjian","year":"1984","journal-title":"J Clin Oncol."},{"key":"2019111822121598300_B5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1097-0142(19860115)57:2<288::AID-CNCR2820570217>3.0.CO;2-5","article-title":"Large noncleaved follicular center cell lymphoma. Clinical features in 53 patients.","volume":"57","author":"Stewart","year":"1986","journal-title":"Cancer."},{"key":"2019111822121598300_B6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1200\/JCO.1993.11.2.218","article-title":"Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group.","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol."},{"key":"2019111822121598300_B7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.1994.12.7.1349","article-title":"Follicular large-cell lymphoma: intermediate or low grade?","volume":"12","author":"Bartlett","year":"1994","journal-title":"J Clin Oncol."},{"key":"2019111822121598300_B8","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.","volume":"85","author":"Martin","year":"1995","journal-title":"Blood."},{"key":"2019111822121598300_B9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","article-title":"Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.","volume":"15","author":"Wendum","year":"1997","journal-title":"J Clin Oncol."},{"key":"2019111822121598300_B10","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood."},{"key":"2019111822121598300_B11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1008330311886","article-title":"Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.","volume":"11","author":"Rodriguez","year":"2000","journal-title":"Ann Oncol."},{"key":"2019111822121598300_B12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0889-8588(05)70468-8","article-title":"Follicular lymphomas: do histologic subtypes predict outcome?","volume":"11","author":"Miller","year":"1997","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019111822121598300_B13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"2019111822121598300_B14","first-page":"162","article-title":"Follicular lymphoma.","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Nathwani","year":"2001"},{"key":"2019111822121598300_B15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.","volume":"1","author":"Mann","year":"1983","journal-title":"Hematol Oncol."},{"key":"2019111822121598300_B16","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3.","volume":"99","author":"Ott","year":"2002","journal-title":"Blood."},{"key":"2019111822121598300_B17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/1097-0142(197709)40:3<1229::AID-CNCR2820400337>3.0.CO;2-F","article-title":"The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation.","volume":"40","author":"Warnke","year":"1977","journal-title":"Cancer."},{"key":"2019111822121598300_B18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/1097-0142(19870415)59:8<1470::AID-CNCR2820590813>3.0.CO;2-K","article-title":"Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma.","volume":"59","author":"Horning","year":"1987","journal-title":"Cancer."},{"key":"2019111822121598300_B19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"a predictive model for aggressive non-Hodgkin's lymphoma.","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med."},{"issue":"2 suppl 3","key":"2019111822121598300_B20","first-page":"4","article-title":"Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens.","volume":"31","author":"Vose","year":"1994","journal-title":"Semin Hematol."},{"key":"2019111822121598300_B21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/10428190290016917","article-title":"CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.","volume":"43","author":"Vose","year":"2002","journal-title":"Leuk Lymphoma."},{"key":"2019111822121598300_B22","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage.","volume":"49","author":"The Non-Hodgkin's Lymphoma Pathologic Classification Project","year":"1982","journal-title":"Cancer."},{"key":"2019111822121598300_B23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2019111822121598300_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analysis and examples.","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer."},{"key":"2019111822121598300_B25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc."},{"key":"2019111822121598300_B26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/biomet\/62.2.269","article-title":"Partial likelihood.","volume":"62","author":"Cox","year":"1975","journal-title":"Biometrika."},{"key":"2019111822121598300_B27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1993.10476296","article-title":"Survival trees by goodness of split.","volume":"88","author":"LeBlanc","year":"1993","journal-title":"J Am Stat Assoc."},{"key":"2019111822121598300_B28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V68.4.837.837","article-title":"What should be the morphologic criteria for the subdivision of follicular lymphomas?","volume":"68","author":"Nathwani","year":"1986","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/6\/2363\/1261750\/h80603002363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/6\/2363\/1261750\/h80603002363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:05:50Z","timestamp":1733904350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/6\/2363\/106516\/A-significant-diffuse-component-predicts-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-07-2298","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,15]]}}}